Fatal bleedings with prasugrel as part of triple antithrombotic therapy

Rev Esp Cardiol (Engl Ed). 2014 Mar;67(3):225-6. doi: 10.1016/j.rec.2013.06.014. Epub 2013 Oct 25.

Authors

Stefano Savonitto¹, Marco Ferri², Elena Corrada³

Affiliations

¹ Division of Cardiolgy, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy. Electronic address: stefano.savonitto@asmn.re.it.
² Division of Cardiolgy, IRCCS Arcispedale S. Maria Nuova, Reggio Emilia, Italy.
³ Cardiovascular Department, Humanitas Clinical and Research Center, Rozzano, Italy.

PMID: 24774401
DOI: 10.1016/j.rec.2013.06.014

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Angioplasty, Balloon, Coronary
Anticoagulants / adverse effects*
Arteriovenous Malformations / pathology
Aspirin / adverse effects
Drug Therapy, Combination
Fatal Outcome
Gastrointestinal Hemorrhage / chemically induced*
Humans
Intracranial Hemorrhages / chemically induced*
Male
Middle Aged
Piperazines / adverse effects*
Platelet Aggregation Inhibitors / adverse effects*
Prasugrel Hydrochloride
Stents / adverse effects
Thiophenes / adverse effects*
Thrombosis / drug therapy
Warfarin / adverse effects

Substances

Anticoagulants
Piperazines
Platelet Aggregation Inhibitors
Thiophenes
Warfarin
Prasugrel Hydrochloride
Aspirin